转移性结直肠癌一线治疗中的不良事件:三项随机试验的毒性随时间(ToxT)分析
该研究对纳入TRIBE、TRIBE2和VALENTINO三项随机试验的1400例转移性结直肠癌患者进行ToxT分析,纵向描述不良事件。结果显示多数化疗相关不良事件在最初几周期最高后下降,FOLFOXIRI/贝伐珠单抗组始终最高;神经毒性随周期增加并出现晚期高级别事件,抗EGFR相关不良事件在维持期仍持续。
要点
- 多数化疗相关不良事件在最初几周期最高后下降,FOLFOXIRI/贝伐珠单抗组始终最高(p < 0.001)。
- 神经毒性随周期增加并出现晚期高级别事件(p < 0.001),手-足综合征发生率逐渐增加但分级未变(p = 0.91)。
- 转为维持治疗可缓解多数不良事件,尤其贝伐珠单抗方案,而抗EGFR相关不良事件可能持续。
核心结论
- 多数化疗相关不良事件(除手-足综合征和神经病变外)在最初几周期达到最高水平后下降,可能由于积极的临床管理。
- 转为维持治疗可缓解多数不良事件,尤其贝伐珠单抗为基础方案,而抗EGFR相关不良事件可能持续。
研究设计与样本
- 对纳入随机TRIBE、TRIBE2和VALENTINO研究的1400例转移性结直肠癌患者进行ToxT评估,纵向描述整个治疗期间的不良事件并比较诱导与维持策略间不良事件随周期的演变。
- 联合治疗4-6个月后,除VALENTINO试验中50%接受帕尼单抗单药的患者外,所有研究推荐5-氟尿嘧啶/亚叶酸钙(5-FU/LV)+贝伐珠单抗或帕尼单抗。
主要发现
- 1400例患者中,42%接受FOLFOXIRI(5-FU/LV、奥沙利铂和伊立替康)/贝伐珠单抗,18%接受FOLFIRI/贝伐珠单抗,24%接受FOLFOX/贝伐珠单抗,16%接受FOLFOX/帕尼单抗。
- 一般和血液学不良事件的平均分级在最初几周期较高,诱导结束后逐渐下降(p < 0.001),且FOLFOXIRI/贝伐珠单抗组始终保持在最高水平(p < 0.001)。
- 神经毒性随周期变得更频繁并出现晚期高级别事件(p < 0.001),而手-足综合征的发生率逐渐增加但分级未变(p = 0.91)。
- 抗VEGF相关不良事件在最初几周期较严重,之后稳定在低水平(p = 0.03),而抗EGFR相关不良事件在维持期仍影响患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical trials, the assessment of safety is traditionally focused on the overall rate of high-grade and serious adverse events (AEs). A new approach to AEs evaluation, taking into account chronic low-grade AEs, single patient's perspective, and time-related information, such as ToxT analysis, should be considered especially for less intense but potentially long-lasting treatments, such as maintenance strategies in metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: We applied ToxT (Toxicity over Time) evaluation to a large cohort of mCRC patients enroled in randomised TRIBE, TRIBE2, and VALENTINO studies, in order to longitudinally describe AEs throughout the whole treatment duration and to compare AEs evolution over cycles between induction and maintenance strategies, providing numerical and graphical results overall and per single patient. After 4-6 months of combination therapy, 5-fluorouracil/leucovorin (5-FU/LV) + bevacizumab or panitumumab was recommended in all studies except for the 50% of patients in the VALENTINO trial who received panitumumab alone. RESULTS: Out of 1400 patients included, 42% received FOLFOXIRI (5-FU/LV, oxaliplatin, and irinotecan)/bevacizumab, 18% FOLFIRI/bevacizumab, 24% FOLFOX/bevacizumab, 16% FOLFOX/panitumumab. Mean grade of general and haematological AEs was higher in the first cycles, then progressively decreasing after the end of induction (p < 0.001), and always remaining at the highest levels with FOLFOXIRI/bevacizumab (p < 0.001). Neurotoxicity became more frequent over the cycles with late high-grade episodes (p < 0.001), while the incidence but not the grade of hand-and-foot syndrome gradually increased (p = 0.91). Anti-VEGF-related AEs were more severe in the first cycles, then setting over at low levels (p = 0.03), while anti-EGFR-related AEs still affected patients during maintenance. CONCLUSIONS: Most of chemotherapy-related AEs (except for HFS and neuropathy) reach the highest level in the first cycles, then decrease, probably due to their active clinical management. Transition to maintenance allows relief from most AEs, especially with bevacizumab-based regimens, while anti-EGFR-related AEs may persist.
引用
- Boccaccino A, Rossini D, Raimondi A, et al. Adverse events during first-line treatments for mCRC: The Toxicity over Time (ToxT) analysis of three randomised trials. Eur J Cancer. 2023. PMID: 37301718. doi:10.1016/j.ejca.2023.05.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。